Ketim Therapeutics is a biotech startup developing blood-based biomarkers for early prediction of mental illnesses, initially focusing on perinatal and postnatal depression (PPD). Their platform aims to enable timely and targeted interventions by detecting PPD before its onset, providing clinicians with non-invasive diagnostic tools.
Funding
Funding not disclosed
Founders
Product
Problem
Current methods for assessing the risk of perinatal and postpartum depression (PPD) rely on subjective self-reporting, leading to under-diagnosis and delayed intervention. The lack of objective, early detection methods hinders proactive treatment strategies for mothers at risk.
Solution
Ketim Therapeutics is developing blood-based biomarker diagnostics for the early prediction and personalized treatment of perinatal mental health disorders, starting with PPD. The company leverages a proprietary database integrating multi-modal patient data, including protein biomarker profiles, clinical information, and health records. Using AI and machine learning, Ketim identifies novel biomarker signatures that can predict PPD risk with high sensitivity and specificity, even before symptoms manifest. This approach enables clinicians to provide timely, targeted interventions and personalized care, improving outcomes for mothers and their families. The integrated platform facilitates biomarker validation, qualification, and seamless integration of biomarker data with clinical records.
Target Audience
The primary target audience includes clinicians, hospitals, and research centers focused on maternal health, particularly those specializing in perinatal and postpartum mental health care.
Features
- Proprietary four-protein biomarker signature for predicting PPD risk with up to 94% sensitivity and specificity at 24 weeks gestation
- AI/ML-enabled platform for biomarker discovery, drug development, and diagnostics in mental health
- Integration of multi-omics data (proteomics, genomics, etc.) with clinical data for enhanced predictive power
- Rigorous biomarker validation and qualification process to ensure accuracy and clinical relevance
- Access to ethically sourced patient data from diverse cohorts
- Advanced curation techniques to ensure data accuracy and depth
- Integration with validated rating scales to build a rich, curated database